Zai Lab Limited Announces Dosing of First Patient in Phase 3 Registration Trial of ZL-2306 (niraparib) for Treatment of Ovarian Cancer Read more about Zai Lab Limited Announces Dosing of First Patient in Phase 3 Registration Trial of ZL-2306 (niraparib) for Treatment of Ovarian Cancer
Zai Lab Limited Announces Closing of U.S. Initial Public Offering of ADSs Read more about Zai Lab Limited Announces Closing of U.S. Initial Public Offering of ADSs
Zai Lab Limited Announces Upsizing of U.S. Initial Public Offering of ADSs Read more about Zai Lab Limited Announces Upsizing of U.S. Initial Public Offering of ADSs
Zai Lab Limited Announces Pricing of U.S. Initial Public Offering of ADSs Read more about Zai Lab Limited Announces Pricing of U.S. Initial Public Offering of ADSs
ZAI Lab announces a global licensing agreement with Sanofi for a novel compound to potentially treat NSCLC Read more about ZAI Lab announces a global licensing agreement with Sanofi for a novel compound to potentially treat NSCLC
ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Read more about ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China
ZAI Lab secures over $30M in Series A financing commitment from leading healthcare investors Read more about ZAI Lab secures over $30M in Series A financing commitment from leading healthcare investors
ZAI Lab announces a global licensing agreement with Sanofi for two novel compounds in chronic respiratory diseases Read more about ZAI Lab announces a global licensing agreement with Sanofi for two novel compounds in chronic respiratory diseases
ZAI Lab Enrolls First Patient in Phase 1 Study of ZL-2102 Read more about ZAI Lab Enrolls First Patient in Phase 1 Study of ZL-2102
Bristol-Myers Squibb and ZAI Lab Enter Licensing Agreement to Develop, Manufacture and Commercialize Brivanib in China Read more about Bristol-Myers Squibb and ZAI Lab Enter Licensing Agreement to Develop, Manufacture and Commercialize Brivanib in China